Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: <scp>iBOIN‐ET</scp>-Reference-Cited by-同舟云学术

Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN‐ET

Published:2022-12-13 Issue: Volume: Page:
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Zhao Yunqi¹^ORCID,Liu Rachael¹^ORCID,Takeda Kentaro²^ORCID

Affiliation:

1. Statistical and Quantitative Sciences Takeda Pharmaceuticals Cambridge Massachusetts USA

2. Data Science Astellas Pharma Global Development, Inc. Northbrook Illinois USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2281

Reference28 articles.

1. Design and Analysis of Phase I Clinical Trials

2. Comparative review of novel model-assisted designs for phase I clinical trials

3. Food and Drug Administration.Considerations for the development of chimeric antigen receptor (CAR) T cell products. Draft guidance for industry.2022.

4. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy

5. Clinical benefit in phase I trials of novel molecularly targeted agents: Does dose matter?

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DOD-Combo: Bayesian dose finding design in combination trials with meta-analytic-predictive prior;Journal of Biopharmaceutical Statistics;2024-03-11

2. BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations;Statistical Methods in Medical Research;2024-03-06

3. A generalized Bayesian optimal interval design for dose optimization in immunotherapy;Pharmaceutical Statistics;2024-01-31

4. A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology;Pharmaceutical Statistics;2023-08-06

5. TITE‐gBOIN‐ET: Time‐to‐event generalized Bayesian optimal interval design to accelerate dose‐finding accounting for ordinal graded efficacy and toxicity outcomes;Biometrical Journal;2023-06-12